The global computational biology market is expected to grow with a CAGR of 19.27%. Factors that are responsible for the growth of the market include increase in bioinformatics research, increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and growth of drug designing and disease modeling.
Bioinformatics is recognized as part of the essential knowledge base of numerous career paths in biomedical research and healthcare. The field of bioinformatics and computational biology has gone through a number of transformations over the past 15 years, establishing itself as a key component of new biology. The use of bioinformatics tools in life sciences has become necessary to analyze experimental data. The huge amounts of data pose a challenge for the biological community, as most biologists are not familiar with informatics and statistical interpretation. An interdisciplinary collaboration was started with an aim to address the need for biologists to understand biological data.
Recent improvements in bioinformatics include capacity-building through activities, such as research funding and training opportunities. Increased funding in bioinformatics is helping in creating more advancements in the field of computational biology.
Key Market Trends
Industry and Commercials Sub-segment is Expected to hold its Highest Market Share in the End User Segment
In the end user segment of the market, the Industry and Commercials sub-segment is believed to have the largest market size and is expected to witness a CAGR of 19.50% during the forecast period.
Computational biology has a wide range of applications in the fields of genomics, proteomics, pharmacogenomics, and drug discovery. For drug discovery and clinical trials, many companies approach third-party services, who have to maintain computational biology setups for carrying out various drug discovery processes. Many third-party services and small laboratories that maintain computational biology setups are expected to gain huge profits, as they successfully reduce the overall time needed for drug discovery and various other scientific experiments.
The software and databases are relatively costlier, and the cost of drug discovery processes vary across countries, which makes many industries opt for outsourcing, thereby, leading to an increased demand for small laboratories and other commercial companies. Hence, with the increase in bioinformatics research, the increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and the growth of drug designing, disease modeling, and personalized medicine, the demand for computational biology for industry and commercial purposes is expected to increase, thereby, driving the market during the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for computational biology and is expected to continue its stronghold for a few more years. The United States is the leading nation in the field of synthetic biology, which is an emerging discipline involving the creation, control, and reprogramming of biological systems. Since 2005, the US government has channelled more than USD 1 billion for the development of computational biology and synthetic biology. The annual average expenditure for the development of computational biology, by the United States government, has been estimated to be USD 140 million.
The overall market for computational biology in the United States is scheduled to grow manifold, over the forecast period, primarily due to high expenditure in drug development endeavors (highest in the world).
The computational biology market is expected to become highly competitive in the near future, as it consists of several major players. With increasing technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices. Companies, like Dassault Systèmes, Chemical Computing Group Inc., Instem Plc. (Leadscope Inc.), Compugen Ltd, and Certara, hold substantial shares in the market.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Increase in Bioinformatics Research
4.2.2 Increasing Number of Clinical Studies in Pharmacogenomics and Pharmacokinetics
4.2.3 Growth of Drug Designing and Disease Modeling
4.3 Market Restraints
4.3.1 Lack of Trained Professionals
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Cellular and Biological Simulation
126.96.36.199 Computational Genomics
188.8.131.52 Computational Proteomics
184.108.40.206 Other Cellular and Biological Simulations (Transcriptomics/Metabolomics)
5.1.2 Drug Discovery and Disease Modelling
220.127.116.11 Target Identification
18.104.22.168 Target Validation
22.214.171.124 Lead Discovery
126.96.36.199 Lead Optimization
5.1.3 Preclinical Drug Development
5.1.4 Clinical Trials
188.8.131.52 Phase I
184.108.40.206 Phase Ii
220.127.116.11 Phase Iii
5.1.5 Human Body Simulation Software
5.2 by Tool
5.2.2 Infrastructure (Hardware)
5.2.3 Analysis Software and Services
5.3 by Service
5.4 by End-user
5.4.2 Industry and Commercials
5.5.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.5.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East & Africa
5.5.5 South America
22.214.171.124 Rest of South America
6.1.1 Dassault Systèmes Se
6.1.3 Chemical Computing Group Ulc
6.1.4 Compugen Ltd
6.1.5 Rosa & Co. LLC
6.1.6 Genedata AG
6.1.7 Insilico Biotechnology AG
6.1.8 Instem plc. (Leadscope Inc.)
6.1.9 Nimbus Discovery LLC
6.1.10 Strand Life Sciences
6.1.12 Simulation Plus Inc.
A selection of companies mentioned in this report includes:
- Dassault Systèmes SE
- Chemical Computing Group ULC
- Compugen Ltd
- Rosa & Co. LLC
- Genedata AG
- Insilico Biotechnology AG
- Instem Plc. (Leadscope Inc.)
- Nimbus Discovery LLC
- Strand Life Sciences
- Simulation Plus Inc.